Clinical trials: Geriatric Population
- Condition Geriatric Population
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
COVID-19
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05329038
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Invasive Group B Streptococcus Disease
Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days
Compare anticapsular antibody levels against Group B Streptococcus at delivery in mothers and their infants who develop disease versus those who do not.
- Trial name
- NCT02099149
- Where
- South Africa
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novartis
Constipation
TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects
The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated by the body and to evaluate whether it is safe and well tolerated.
- Trial name
- NCT01655771
- Testing
- TD-1211 Dose 1, TD-1211 Dose 2
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
Covid19
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy…
- Trial name
- COSMIC (NCT05280717)
- Testing
- sotrovimab
- Where
- 10 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Healthy Volunteers
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.
- Trial name
- NCT06314880
- Testing
- Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose), Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Incontinence-associated Dermatitis
How Wet Pads Affect Elderly Skin: Measuring Changes in the Skin Barrier
The main aim of this study is to describe the effects of dry or wet incontinence pad material on the skin barrier function by measuring the changes of the stratum corneum on healthy participants due to the application of pads…
- Trial name
- DROPBOX (NCT07164898)
- Testing
- Test patches
- Where
- Sweden
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Essity Hygiene and Health AB
Healthy
A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers
The purpose of this study is to assess safety, tolerability and pharmacokinetics of TC-5214 in elderly healthy Japanese volunteers.
- Trial name
- NCT01392820
- Testing
- TC-5214
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study Investigating the Effect of Floradapt Mature Immune Defense on Nutrient Uptake and Digestive Health in a Healthy Elderly Population
This trial will be investigating the effect for Floradapt Mature Immune Defense on nutrient uptake and digestive health in a healthy elderly population.
- Trial name
- NCT04147923
- Testing
- Floradapt Mature Immune Defense + Multivitamin
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Kaneka Americas Holding Inc.
Tuberculosis, TB Infection
A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations
A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia
- Trial name
- NCT07647107
- Testing
- LipovaxinS4-EAH (Middle Dose), LipovaksinS4-EAH (High Dose)
- Where
- Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05069129
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08), Inactivated COVID-19 vaccine (Vero cells), 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
- Where
- United Arab Emirates
- Volunteers
- 1,848 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Latent Tuberculosis Infection (LTBI)
C-TST for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Indonesia
This is an operational research in household/close contacts of confirmed TB patients to evaluate the effectiveness of C-TST compared to IGRA test in identifying latent TB cases using parameters of effectiveness and safety.
- Trial name
- C-TST (NCT07587164)
- Testing
- Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST)
- Where
- Indonesia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV)
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
Phase 1 clinical trial to evaluate the safety of RSV-1 and RSV-2 vaccines in healthy adults aged 19 to 80 years who have voluntarily given written consent to participate in this study.
- Trial name
- EuRSV (NCT06216093)
- Testing
- EuRSV
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Healthy
Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of AZD5213 in healthy young and elderly Japanese subjects
- Trial name
- NCT01335451
- Testing
- AZD5213
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years
This is an open-labelled, bridging phase Ⅲ clinical trial of COVID-19 Vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05137418
- Testing
- COVID-19 Vaccine,Inactivated
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Influenza
Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in elderly subjects.
- Trial name
- NCT01767896
- Testing
- ASP7374, approved egg-derived TIV
- Where
- 3 sites in Japan
- Volunteers
- 1,020 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04992208
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 31,041 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19
Immunogenicity of an Inactivated COVID-19 Vaccine
This study is an open phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.
- Trial name
- NCT05198336
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 395 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Hepatitis B Vaccine
Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.
The purpose of this study is to assess the persistence of immunity to hepatitis B in children who received three consecutive doses of HBV vaccine (EngerixTM-B) in infancy.
- Trial name
- NCT00519649
- Testing
- Engerix™-B Kinder
- Where
- 35 sites in Germany
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers
The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune…
- Trial name
- NCT01229371
- Testing
- Inflexal V influenza vaccine (CSL HA Antigen) 2010, Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011
- Where
- 2 sites in Switzerland
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV